BTC Health Ltd Registered · ASX:BTC
BTC Health Ltd Registered — BTC Health — Investor Presentation (May 2019)
29 slides from BTC Health Ltd Registered's investor presentation, May 13, 2019
Slide 1: Investor Presentation: Hospital Infusion Business Acquisition and Capital Raising
For personal use only Investor Presentation Hospital Infusion Business Acquisition and Capital Raising 13 May 2019 Richard Treagus Executive 1 Chairman
Slide 2: Forward Looking Statements
Forward Looking Statements For personal use only This presentation contains forward looking statements that involve risks and uncertainties. Although we believe that the expectations and assumptions reflected in the forward looking statements are reasonable at this time, BTC health can give no assur
Slide 3: Executive Summary
Executive Summary BTC health is executing on its strategy of building a high-growth, sustainable medical products company in the Australian and NZ markets. BTC health is a fully compliant For personal use only Pooled Development Fund (PDF) that provides both the company and its shareholders with acc
Slide 4: Board of Directors
Board of Directors For personal use only Richard Treagus – Executive Chairman BScMed, MBChB, MPharmMed, MBA, MAICD. Richard is a physician and entrepreneur with more than 20 years’ experience across the international pharmaceutical and biotechnology industry. Richard is Executive Chairman of Neuren
Slide 5: Highly capable and experienced executive team
Highly capable and experienced executive team For personal use only Richard Treagus – Executive Chairman • More than 25 years experience in the international pharmaceutical and healthcare industry • Formerly head of sales, marketing and business development at Aspen Pharmacare and Sigma • An extensi
Slide 6: Pooled Development Fund Overview
Pooled Development Fund Overview A beneficial structure for shareholders For personal use only BTC health is registered as a Pooled Development Fund A (PDF), giving the company and its shareholders access to substantial tax concessions and benefits.* B Shareholders are entitled to concessionary tax
Slide 7: BTC health Structure
BTC health Structure For personal use only Bio101 – 100% interest 01 Bio101 provides finance and administration solutions to companies in the Australian life sciences sector, such as accounting, company secretarial, taxation, grant applications, payroll administration, business development, royalty
Slide 8: Vision and Growth Strategy
Vision and Growth Strategy BTC health’s vision is to be a leading supplier of specialized medical products in Australia and NZ For personal use only Leverage partnering, Primary focus for product growth is the hospital development and channel and commercialisation specialized products capabilities t
Slide 9: Hospital Infusion Business Acquisition and Capital Raising
For personal use only Hospital Infusion Business Acquisition and Capital Raising A transformative acquisition for BTC health 9
Slide 10: Acquisition Overview
Acquisition Overview BTC heath Limited (“BTC”) is pleased to announce a compelling acquisition, which will be funded For personal use only by a private placement of $8.0m. Acquiring the Hospital Infusion Transfer and employment of key Business from Admedus Limited, nominated staff comprising a natio
Slide 11: Summit Medical Products
Summit Medical Products Summit Medical Products, Inc. is a privately-held, employee-owned company located in For personal use only Salt Lake City, Utah, USA. Summit has broad experience in the design, development and distribution of medical products. Summit’s primary focus is the ambIT® infusion pum
Slide 12: Summit Medical Products
Summit Medical Products For personal use only Target customers: ambIT® infusion pumps are sold to hospitals, clinics, and physicians. In addition, various militaries around the world use the ambIT® pump. The ambIT® pump has been approved by the military for use on fixed wing (airplanes) and helicopt
Slide 13: ambIT infusion pumps
ambIT® infusion pumps Innovative ambulatory infusion pumps are a simple, accurate cost- For personal use only effective solution for post-operative local anesthetic infusions. ambIT® Continuous Accurate infusion delivery, providing a simple, sophisticated solution for continuous infusions. Clinical
Slide 14: Hospital Infusion - Other Products
Hospital Infusion - Other Products For personal use only ELDOR Wound Catheter Specialised fenestrated catheters for infusion of local anesthetic into surgical sites for post-operative pain management. CSEN Ultrasound guided needles Rainbow Tray™ An innovative, simple colour-coded anaesthetic tray fo
Slide 15: Australian Hospital Market
Australian Hospital Market For personal use only PUBLIC HOSPITALS* • 695 Public Hospitals with 62,000 beds Hospital expenditure continues to grow • $67 billion recurring expenditure in public hospitals (increased by 3.2% after inflation adjustment) • 13% of this amount ($8.7 billion) spent on 1300+
Slide 16: Hospital Infusion Business
Hospital Infusion Business Existing customer base Historic sales and forecast For personal use only • Sales of infusion products into 126 hospitals. • Opportunity to increase sales within existing customer base and beyond. • Capacity to introduce new hospital products into existing sales team. Annua
Slide 17: Hospital Infusion Business
Hospital Infusion Business For personal use only • >95% of current sales within Australia • Existing hospital customers in all major cities and regional centers • Experienced national sales and specialist education team • Third party logistics (3PL) provider in Perth, WA • Head office - Melbourne •
Slide 18: Acquisition Growth Strategy
Acquisition Growth Strategy Hospital Infusion acquisition provides BTC with infrastructure and platform for growth, For personal use only boosting BTC health revenue. Exclusive Experienced distribution national hospital sales agreements and team product supply contracts Medical Established customer
Slide 19: Significant Opportunities in the Pipeline
Significant Opportunities in the Pipeline For personal use only Exclusive supply agreements Targeting 1-2 new product for Australia and New Zealand introductions per year Typical incremental revenues Strong synergies with of $1-3M p.a. for each product established and experienced (30-50% margin) hos
Slide 20: New Product Pipeline
New Product Pipeline For personal use only CAMURUS AB (Sweden) - Addressable market 20,000 cancer patients p.a. (Grade 3 & 4 Oral mucositis) - Estimated sales potential approximately $750k p.a. • Exclusive license agreement for Episil® oral liquid, a unique and patent-protected product to relieve or
Slide 21: Hospital Infusion Business – positive sales trend
Hospital Infusion Business – positive sales trend For personal use only Sales Value – 12-month MAT (A$) Annual Growth 14% p.a. 21
Slide 22: Hospital & Infusion Business - Financials and outlook
Hospital & Infusion Business - Financials and outlook 2019 FY* 2020 FY 2021 FY 2022 FY 2023 FY Financial Performance For personal use only ($’000) ($’000) ($’000) ($’000) ($’000) Revenue - Infusion acquisition 577 7,033 8,018 9,140 10,420 - New products in-licensed - 318 1,671 3,098 4,380 Total Reve
Slide 23: Corporate Snapshot
Corporate Snapshot 12-month Share Price Performance For personal use only ASX ticker BTC Market capitalisation $11.1 million Share price as at 10 May $0.085 2019 Shares on issue 130.3 million Employee Share Options 2.5 million Board/Management 30% ownership Cash at bank as at 30 April $1.5 million 2
Slide 24: Terms of Hospital Infusion acquisition
Terms of Hospital Infusion acquisition For personal use only • Purchase consideration of $6.3m • Business assets being acquired include: • Long term supplier agreements • Transfer of existing field force • Transfer of Hospital customer relationships • Approximately $1.75m of working capital (invento
Slide 25: Equity Raising Overview
Equity Raising Overview BTC intends to raise $8.0m via a two tranche private placement followed with a Share For personal use only Purchase Plan. Private Placement • $8.0m placement to sophisticated and wholesale investors • Offer price of $0.08 per new share • Each participant will participate in b
Slide 26: Sources and Uses of Funds
Sources and Uses of Funds Source Uses For personal use only Private Placement – Tranche 1 $2.6m Purchase consideration $6.3m Private Placement – Tranche 2 $5.4m Transaction fees including Legal, $0.6m Stockbroker and Advisers Integration Costs associated with $0.25m the Hospital Infusion Business In
Slide 27: Appendices: Financing Timetable
Appendices Financing Timetable For personal use only Trading Halt and announcement of private placement Monday, 13 May 2019 Private placement bookbuild opens Monday, 13 May 2019 Private placement closes Tuesday, 14 May 2019 Trading halt lifted and announcement of private placement Wednesday, 15 May
Slide 28: Risks
Risks Key supplier risks For personal use only The supply agreement with Summit Medical Inc. accounts for >98% of the current revenues of the business. An unexpected termination of product supply, or a material change in the supply terms would have a significant impact on the business. Key customer
Slide 29: For personal use only
a a AjuoO SSN feuosied 10}